Black Diamond Therapeutics (BDTX) Current Assets (2018 - 2026)
Black Diamond Therapeutics' (BDTX) quarterly Current Assets came in at $123.0 million in Q1 2026, down 21.01% YoY from $155.7 million in Q1 2025, and down 7.15% on a QoQ basis from $132.4 million in Q4 2025.
Black Diamond Therapeutics (BDTX) Current Assets (2018 - 2026) Analysis & Trends
Black Diamond Therapeutics (BDTX) has 9 years of Current Assets data on file, last reported at $123.0 million in Q1 2026.
- Quarterly Current Assets fell 21.01% year-over-year to $123.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $123.0 million (down 21.01% YoY) and the FY2025 annual result came in at $132.4 million, up 30.9% from the prior year.
- Current Assets eased to $123.0 million in Q1 2026, from $132.4 million in the prior quarter.
- In the past five years, Current Assets ranged from a high of $188.3 million in Q1 2022 to a low of $93.0 million in Q2 2023.
- A 5-year average of $133.9 million and a median of $132.4 million in 2025 frame the typical range for Current Assets.
- Annual changes were most pronounced in 2023 — Current Assets plunged 44.83% — and 2024, when it jumped 36.31%.
- Tracing BDTX's Current Assets over 5 years: stood at $127.7 million in 2022, then rose by 4.96% to $134.0 million in 2023, then decreased by 24.51% to $101.2 million in 2024, then jumped by 30.9% to $132.4 million in 2025, then declined by 7.15% to $123.0 million in 2026.
- The last three Current Assets figures came in at $123.0 million (Q1 2026), $132.4 million (Q4 2025), and $139.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.76 Bn |
| 10 | Black Diamond Therapeutics | 125.92 Mn | 15.42 Mn | - | 115.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 115.39 Mn |
| Mar 31, 2026 | 122.97 Mn |
| Dec 31, 2025 | 132.44 Mn |
| Sep 30, 2025 | 138.99 Mn |
| Jun 30, 2025 | 146.73 Mn |
| Mar 31, 2025 | 155.68 Mn |
| Dec 31, 2024 | 101.18 Mn |
| Sep 30, 2024 | 115.54 Mn |
| Jun 30, 2024 | 126.75 Mn |
| Mar 31, 2024 | 118.81 Mn |
| Dec 31, 2023 | 134.03 Mn |
| Sep 30, 2023 | 147.05 Mn |
| Jun 30, 2023 | 92.99 Mn |
| Mar 31, 2023 | 107.98 Mn |
| Dec 31, 2022 | 127.71 Mn |
| Sep 30, 2022 | 150.98 Mn |
| Jun 30, 2022 | 168.56 Mn |
| Mar 31, 2022 | 188.30 Mn |
| Dec 31, 2021 | 215.70 Mn |
| Sep 30, 2021 | 241.55 Mn |